Vernalis PLC Vernalis Notes RedoxTherapies Acquisition by Juno (2653E)
July 15 2016 - 2:00AM
UK Regulatory
TIDMVER
RNS Number : 2653E
Vernalis PLC
15 July 2016
15 July 2016
LSE: VER
Vernalis Notes the Acquisition of RedoxTherapies by Juno
Therapeutics
RedoxTherapies to Continue to Pursue Development of Vipadenant
(V2006)
Vernalis plc ("Vernalis" or the "Company") notes the
announcement by Juno Therapeutics, Inc. ("Juno") (NASDAQ: JUNO)
that RedoxTherapies, Inc. ("RedoxTherapies") and Juno have entered
into a share purchase agreement, pursuant to which Juno acquired
the outstanding shares of RedoxTherapies. After the acquisition,
RedoxTherapies retains its worldwide license to vipadenant (V2006).
The licence agreement continues to include clinical and regulatory
milestones, as well as royalties on commercial sales. Vernalis
originally entered into the license agreement with RedoxTherapies
in October 2014.
Vipadenant is a small molecule A2A receptor antagonist that has
the potential to disrupt an immunosuppressive mechanism of tumor
protection, generating improved efficacy for immunotherapies of
certain cancers when used in combination.
Ian Garland, CEO of Vernalis commented "We are delighted that
Juno, a leader in CAR and TCR technologies, has acquired
RedoxTherapies. We look forward to seeing RedoxTherapies continue
to pursue the development of vipadenant."
This announcement contains inside information.
-- ends --
Enquiries:
+44 (0) 118 938
Vernalis plc: 0015
Ian Garland, Chief Executive
Officer
David Mackney, Chief Financial
Officer
Canaccord Genuity Limited (Nominated +44 (0) 20 7523
Adviser): 8000
Dr Julian Feneley
Rupert Winckler
Henry Fitzgerald-O'Connor
Emma Gabriel
+44 (0)20 7408
Shore Capital (Joint Broker): 4090
Bidhi Bhoma
Toby Gibbs
+44 (0) 20 3727
FTI Consulting: 1000
Ben Atwell
Simon Conway
Stephanie Cuthbert
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage
pharmaceutical company with significant expertise in drug
development. The Group has three approved products: Tuzistra(R) XR
targeting the US prescription cough-cold market; Moxatag(R) , a
once-a-day formulation of the antibiotic, amoxicillin, indicated
for the treatment of tonsillitis and/or pharyngitis secondary to
Streptococcus pyogenes in adults and pediatric patients 12 years
and older; and frovatriptan for the acute treatment of migraine. It
has an exclusive licensing agreement to develop and commercialise
multiple novel products focussed on the US prescription cough-cold
market as well as eight programmes in its NCE development pipeline.
Vernalis has also significant expertise in fragment and structure
based drug discovery which it leverages to enter into
collaborations with larger pharmaceutical companies. The Company's
technologies, capabilities and products have been endorsed over the
last five years by collaborations with leading pharmaceutical
companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK,
Genentech, Lundbeck, Menarini, Novartis, Servier, Taisho, and
Tris.
For further information about Vernalis, please visit
www.vernalis.com.
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that
reflect the Company's current expectations regarding future events
including the clinical development and regulatory clearance of the
Company's products, the Company's ability to find partners for the
development and commercialisation of its NCE pipeline, the
Company's ability to successfully commercialise its cough-cold
products and Moxatag(R) through its own sales force, as well as the
Company's future capital raising activities. Forward-looking
statements involve risks and uncertainties. Actual events could
differ materially from those projected herein and depend on a
number of factors including the success of the Company's research
strategies, the applicability of the discoveries made therein, the
successful and timely completion of clinical studies, the
uncertainties related to the regulatory process, the ability of the
Company to identify and agree beneficial terms with suitable
partners for the commercialisation and/or development of its
products, as well as the achievement of expected synergies from
such transactions, the acceptance of Tuzistra(R) XR, Moxatag(R) ,
frovatriptan and other products by consumers and medical
professionals, the successful integration of completed mergers and
acquisitions and achievement of expected synergies from such
transactions, and the ability of the Company to identify and
consummate suitable strategic and business combination
transactions.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQUSRARNBABAUR
(END) Dow Jones Newswires
July 15, 2016 02:00 ET (06:00 GMT)
Vernalis (LSE:VER)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vernalis (LSE:VER)
Historical Stock Chart
From Oct 2023 to Oct 2024